On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on the news.
It wasn’t a marriage made in heaven. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers, and that direct access to Wegovy won’t be available via NovoCare Pharmacy to Hims & Hers members.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Here’s what investors need to know about the implications of the termination of the short-lived deal between these two healthcare companies.
Image source: Getty Images.
Why did Novo Nordisk end its collaboration with Hims & Hers?
Novo Nordisk issued an unusually blunt press release explaining its decision to stop working with Hims & Hers. The Swedish drugmaker stated:
Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put[s] patient safety at risk.
Dave Moore, executive vice president of Novo Nordisk’s U.S. Operations, said, “Novo Nordisk is firm on our position and protecting patients living with obesity.” He added, “When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy.”
The two companies had clashed earlier this year after Hims & Hers ran a TV commercial during the Super Bowl that promoted compounded GLP-1 medications as a less-expensive alternative to Wegovy and other branded GLP-1 products. Novo Nordisk quickly fired back with an ad in The New York Times and USA Today that a spokesperson said was a “direct response” to Hims & Hers’ commercial.
What was Hims & Hers’ response to Novo Nordisk’s allegations?
As of the market close on Monday, Hims & Hers had not issued an official press release about Novo Nordisk’s allegations. However, Hims & Hers CEO Andrew Dudum posted on X (formerly Twitter) about his thoughts on the matter:
We are disappointed to see Novo Nordisk management misleading the public.
In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to…
— andrewdudum (@AndrewDudum) June 23, 2025
According to Dudum, Novo Nordisk “pressured” Hims & Hers to “steer patients to Wegovy, regardless of whether it was clinically best for patients.” He declared, “We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice.”
How will this impact Hims & Hers?
Hims & Hers stock plunged nearly 35% on Monday following Novo Nordisk’s announcement. This steep sell-off indicates how much the termination of the Wegovy deal could impact Hims & Hers.
In its first-quarter investor presentation, Hims & Hers listed achieving “long-term leadership position in weight loss” as its top priority. And the company put “integration of NovoCare” (a reference to offering Wegovy via Novo Nordisk’s direct-access pharmacy platform) first among the ways it planned to be the long-term leader in the weight-loss market.
Dudum insisted in his social media post on Monday, “We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.” However, Hims & Hers will only be able to sell a personalized compounded version of Wegovy when healthcare professionals believe that it is clinically necessary for a patient. This will severely limit Hims & Hers’ ability to offer one of the most popular weight-loss drugs on the market.
How will this impact Novo Nordisk?
Novo Nordisk’s share price fell as well on Monday. However, the big pharma stock tumbled only around 5%, reflecting a much more muted impact on its business from scrapping the deal with Hims & Hers.
Wegovy will still be available on some telehealth platforms. Moore stated, “We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety — and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action.”
Hims & Hers isn’t the only telehealth company that entered into a collaboration with Novo Nordisk in April. LifeMD also secured a similar deal that remains in place. Its shares were down roughly 3% on Monday.
Should you invest $1,000 in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $664,089!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $881,731!*
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
